IRON · Disc Medicine, Inc.
$82.67
+0.26 (+0.32%)
At close · Aug 26
Market Cap
$3.16B
Shares
38.39M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$212.18M
-94%
FY2025
Diluted EPS
-$6.01
-51.8%
FY2025
Operating Cash Flow
-$180.39M
-92.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $189.4M | $170.64M | $96.67M | $69.26M | $33.44M | $25.17M | $28.17M | |
| $30.45M | — | — | $21.86M | $14.04M | $5.76M | $5.87M | |
| $79.87M | $65.38M | $33.05M | $21.86M | — | — | — | |
| — | $281K | $156K | $100K | $89K | $32K | — | |
| $269.27M | $236.02M | $129.72M | $91.13M | $47.48M | $30.93M | $34.04M | |
| -$269.27M | -$236.02M | -$129.72M | -$91.13M | -$47.48M | -$30.93M | -$34.04M | |
| $3.55M | $3.61M | $572K | $0 | — | $2.16M | $6.83M | |
| $23.69M | $24.2M | $20.72M | $14.8M | $648K | -$5.04M | — | |
| -$245.58M | -$211.82M | -$109M | -$76.33M | -$46.83M | — | — | |
| $310K | $361K | $355K | $99K | $0 | — | — | |
| -$245.89M | -$212.18M | -$109.36M | -$76.43M | -$46.83M | -$35.97M | -$40.84M | |
| -$103.48M | — | — | -$76.43M | -$46.83M | -$35.97M | — | |
| -$247.77M | -$211.51M | -$109.07M | -$76.43M | — | — | — | |
| USD/shares | — | -$6.01 | -$3.96 | -$3.42 | -$45.05 | -$40.95 | — |
| USD/shares | — | -$6.01 | -$3.96 | -$3.42 | -$45.05 | -$40.95 | — |
| shares | — | 35.3M | 27.61M | 22.32M | 1.04M | 878.41K | 503.84K |
| shares | — | 35.3M | 27.61M | 22.32M | 1.04M | 878.41K | 503.84K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.69×
EV/EBIT
—
Peer median 17.16×
P/E (TTM)
—
Peer median 18.06×
Peer medians compare against the 227 similar-size Biotechnology companies (of 534 listed).
Key facts
CIK
1816736
CUSIP
254604101
13F (30d)
201 filings
200 filers
Visit website
Investor relations